Sherafati Chaleshtori Ali, Marzhoseyni Zeynab, Saeedi Negin, Azar Bahadori Rosita, Mollazadeh Samaneh, Pourghadamyari Hossein, Sajadimoghadam Esmaeil, Abbaszadeh-Goudarzi Kazem, Moradi Hasan-Abad Amin, Sharafati Chaleshtori Reza
Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Department of Orthopedics, Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Front Mol Biosci. 2024 Jul 30;11:1412325. doi: 10.3389/fmolb.2024.1412325. eCollection 2024.
The result of infection of bone with microorganisms is osteomyelitis and septic arthritis. Methicillin-resistant (MRSA) is responsible for most of its cases (more than 50%). Since MRSA is resistant to many treatments, it is accompanied by high costs and numerous complications, necessitating more effective new treatments. Recently, development of gelatin nanoparticles have attracted the attention of scientists of biomedicine to itself, and have been utilized as a delivery vehicle for antibiotics because of their biocompatibility, biodegradability, and cost-effectiveness. Promising results have been reported with gelatin modification and combinations with chemical agents. Although these findings have been suggested that gelatin has the potential to be a suitable option for continuous release of antibiotics in osteomyelitis and septic arthritis treatment, they still have not become routine in clinical practices. The most deliver antibiotic using gelatin-derived composites is vancomycin which is showed the good efficacy. To date, a number of pre-clinical studies evaluated the utility of gelatin-based composites in the management of osteomyelitis. Gelatin-based composites were found to have satisfactory performance in the control of infection, as well as the promotion of bone defect repair in chronic osteomyelitis models. This review summarized the available evidence which provides a new insight into gelatin-derived composites with controlled release of antibiotics.
微生物感染骨骼的结果是骨髓炎和脓毒性关节炎。耐甲氧西林金黄色葡萄球菌（MRSA）是其大多数病例（超过50%）的病因。由于MRSA对许多治疗方法具有抗性，它伴随着高昂的成本和众多并发症，因此需要更有效的新治疗方法。最近，明胶纳米颗粒的开发引起了生物医学科学家的关注，并且由于其生物相容性、可生物降解性和成本效益而被用作抗生素的递送载体。明胶改性以及与化学试剂的组合已报道有前景的结果。尽管这些发现表明明胶有潜力成为骨髓炎和脓毒性关节炎治疗中持续释放抗生素的合适选择，但它们在临床实践中仍未成为常规方法。使用明胶基复合材料递送最多的抗生素是万古霉素，其显示出良好的疗效。迄今为止，一些临床前研究评估了明胶基复合材料在骨髓炎治疗中的效用。在慢性骨髓炎模型中，发现明胶基复合材料在控制感染以及促进骨缺损修复方面具有令人满意的性能。这篇综述总结了现有证据，为具有抗生素控释功能的明胶基复合材料提供了新的见解。
